Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01408888 · ClinicalTrials.gov registry record · Phase 1
A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT01408888: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT01408888 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 29 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01408888, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to study the effect of LY2189265 on how the body absorbs and processes a Type 2 Diabetes Mellitus (T2DM) drug (sitagliptin) and how sitagliptin affects LY2189265 when they are taken together. The duration of participation in this study is expected to be approximately 61 days. The study requires 2 clinic confinements (one of 2 nights and one of 19 nights duration). The study involves 3 injections, subcutaneous, of 1.5 milligrams (mg) LY2189265 and 18 daily doses of 100 mg sitagliptin tablets administered orally.
Primary Outcome
Area under the sitagliptin pharmacokinetic (PK) concentration versus time curve (AUC \[0-tau\]) during one dosing interval (24 hours) is summarized.
Interventions
- DRUG Sitagliptin
- BIOLOGICAL LY2189265
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
What the finished NCT01408888 record still lists
NCT01408888 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 2 interventions - of which Sitagliptin is the first listed.
NCT01408888 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01408888 about?
NCT01408888 is a clinical study titled "A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes". The purpose of this study is to study the effect of LY2189265 on how the body absorbs and processes a Type 2 Diabetes Mellitus (T2DM) drug (sitagliptin) and how sitagliptin affects LY2189265 when they are taken together. The duration of participation in this study is expected to be approximately 61...
What is the current status of trial NCT01408888?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2011-08. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01408888?
The interventions under investigation include: Sitagliptin (DRUG), LY2189265 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01408888?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01408888's enrollment target sits among peer trials
29 1440th of 2000 higher than 554 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia